Bafna Pharmaceuticals Ltd vs Pentokey Organy India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 137.5 as of 06 May 15:30 . The P/E Ratio of Bafna Pharmaceuticals Ltd changed from 55.8 on March 2021 to 42.6 on March 2025 . This represents a CAGR of -5.26% over 5 yearsThe P/E Ratio of Pentokey Organy (India) Ltd changed from 8.2 on March 2023 to 81.2 on March 2025 . This represents a CAGR of 114.74% over 3 years The Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 324.8 crore on March 2021 to ₹ 177.42 crore on March 2025 . This represents a CAGR of -11.39% over 5 yearsThe Market Cap of Pentokey Organy (India) Ltd changed from ₹ 6.83 crore on March 2021 to ₹ 19.84 crore on March 2025 . This represents a CAGR of 23.77% over 5 years The revenue of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 39.51 crore as compare to the Sep '25 revenue of ₹ 36.65 crore. This represent the growth of 7.8% The revenue of Pentokey Organy (India) Ltd for the Dec '25 is ₹ -2.01 crore as compare to the Sep '25 revenue of ₹ 1.09 crore. This represent the decline of -284% The ebitda of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 4.27 crore as compare to the Sep '25 ebitda of ₹ 5.46 crore. This represent the decline of -21.79% The ebitda of Pentokey Organy (India) Ltd for the Dec '25 is ₹ -0.29 crore as compare to the Sep '25 ebitda of ₹ 0.14 crore. This represent the decline of -307% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ -0.72 crore to ₹ 1.84 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Pentokey Organy (India) Ltd changed from ₹ 0.05 crore to ₹ -0.29 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Pentokey Organy (India) Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

About Pentokey Organy (India) Ltd

Pentokey Organy (India) Ltd was incorporated on November 26, 1986.
The Company is engaged in the trading of Pharmaceutical products such as Acetic Acid, Ethyl Acetate and Acetaldehyde.
Ethyl Acetate is preferred by customers in all markets as it is fast replacing the petroleum-based solvents such as Toluene, MEK (Methyl Ethyl Ketone), MIBK (Methyl Iso Butyl Ketone) etc. In 2012-13, the production of intermediate product namely Acetic Acid was not competitive due to market prices.
Company therefore purchased the Acetic Acid from market instead of producing the same from Ethanol or Acetaldehyde.
As a result of this, production of Acetaldehyde, which is an intermediate product for Acetic Acid, was low.

FAQs for the comparison of Bafna Pharmaceuticals Ltd and Pentokey Organy (India) Ltd

Which company has a larger market capitalization, Bafna Pharmaceuticals Ltd or Pentokey Organy (India) Ltd?

Market cap of Bafna Pharmaceuticals Ltd is 325 Cr while Market cap of Pentokey Organy (India) Ltd is 25 Cr

What are the key factors driving the stock performance of Bafna Pharmaceuticals Ltd and Pentokey Organy (India) Ltd?

The stock performance of Bafna Pharmaceuticals Ltd and Pentokey Organy (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bafna Pharmaceuticals Ltd and Pentokey Organy (India) Ltd?

As of May 6, 2026, the Bafna Pharmaceuticals Ltd stock price is INR ₹137.5. On the other hand, Pentokey Organy (India) Ltd stock price is INR ₹41.07.

How do dividend payouts of Bafna Pharmaceuticals Ltd and Pentokey Organy (India) Ltd compare?

To compare the dividend payouts of Bafna Pharmaceuticals Ltd and Pentokey Organy (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.